Please login to the form below

Not currently logged in
Email:
Password:

Astellas boosts US antibody centre with new hires

Wolfgang Noe and Frank Hudson join pharma company's Santa Monica affiliate Agensys

Astellas has appointed Wolfgang Noe and Frank Hudson to its US antibody research affiliate Agensys.

Noe joins as vice president of process sciences and manufacturing and comes to the Santa Monica-based company from Biogen Idec, where he spent seven years, most recently as vice president of strategic development and technical alliances.

Prior to Biogen Noe began his pharma career with Boehringer-Ingelheim Pharmaceuticals in Germany.

In his new role at Agensys he will be responsible for manufacturing development and manufacturing of clinical and preclinical drug supplies.

Meanwhile, Agensys has appointed Frank Hudson as vice president of finance.

He has more than 20 years of pharmaceutical experience and moves to Agensys from the Mannkind Corporation where he served as vice president of finance since 2007.

At Agensys, Hudson will be responsible for finance, procurement and information technology.

"Frank and Wolfgang each bring a wealth of experience from the biopharma industry to their respective positions," said Sef Kurstjens, president and CEO of Agensys. "Frank's experience in research and development finance is exactly what we were looking for in our candidates, and Wolfgang's record in preclinical and clinical drug development brings additional strength to our operations."

Agensys, which was acquired by Astellas in 2007, focuses on antibody product discovery and development, and plans to finish work on a new research and development facility in 2013.

2nd December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics